MSL3 and ovarian cancer: Using another ovarian cancer clinical dataset, (GSE3149), the survival for patients with tumors having low expression of MSL3 and ITGB3BP was again significantly shorter than that of the high expression group (Supplementary Fig. S6a,b, p < 0.05 for each).